Pfizer: Challenges Loom Amid Overvaluation (NYSE:PFE)
1. Pfizer's revenue growth is overshadowed by regulatory and debt challenges. 2. Stock is considered overvalued; fair price is projected below $25. 3. Market analysts predict low dividend growth of under 2% for two years. 4. Stagnant performance persists despite previous FY revenue growth of 24.7%. 5. Analyst downgrades indicate concerns about Pfizer's competitive viability.